Zevra Therapeutics (ZVRA) director awarded 30,000 stock options at set price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Zevra Therapeutics director Alvin Shih received a grant of 30,000 stock options to buy common stock at an exercise price equal to the Nasdaq closing price of $11.17 on June 4, 2026. The options vest 100% on the earlier of the first anniversary, the day before the first annual stockholders meeting after grant, or immediately before a change in control, subject to his continued board service, and expire on June 3, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shih Alvin
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
- The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Key Figures
Options granted: 30,000 options
Exercise price: $11.17 per share
Underlying shares: 30,000 shares
+3 more
6 metrics
Options granted
30,000 options
Stock Option (right to buy) grant on June 4, 2026
Exercise price
$11.17 per share
Equal to Nasdaq closing price on June 4, 2026
Underlying shares
30,000 shares
Common stock underlying granted options
Post-grant option holdings
30,000 options
Total derivative holdings following this reported transaction
Option expiration
June 3, 2036
Expiration date of the stock option award
Vesting schedule
100% cliff vesting
Earlier of first anniversary, pre-annual meeting, or change in control
Key Terms
Stock Option (right to buy), exercise price, non-employee director compensation policy, change in control, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
non-employee director compensation policy financial
"pursuant to the Issuer's tenth amended and restated non-employee director compensation policy"
change in control financial
"immediately prior to a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
vesting financial
"shares subject to the option shall vest on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Zevra Therapeutics (ZVRA) director Alvin Shih report on this Form 4?
Alvin Shih reported receiving 30,000 stock options as compensation for serving on Zevra’s board. These options give him the right to buy common shares at a fixed exercise price set on June 4, 2026, based on the Nasdaq closing price.
How many Zevra Therapeutics (ZVRA) options did Alvin Shih receive?
Alvin Shih received stock options covering 30,000 shares of Zevra common stock. All 30,000 options were newly granted, and following this grant he holds options for 30,000 shares under this award, subject to the vesting conditions described in the filing footnotes.
What is the exercise price of Alvin Shih’s Zevra (ZVRA) stock options?
The exercise price is equal to the June 4, 2026 Nasdaq closing price of Zevra’s common stock, stated as $11.17 per share. This means Shih can buy shares at $11.17 once the options vest, regardless of future market price movements.
When do Alvin Shih’s Zevra (ZVRA) stock options vest?
One hundred percent of the options vest on the earliest of three events: the first anniversary of the June 4, 2026 grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, assuming continued board service.
Why did Zevra Therapeutics (ZVRA) grant these options to Alvin Shih?
The options were granted as compensation for Alvin Shih’s service on Zevra’s board of directors. They were awarded under Zevra’s tenth amended and restated non-employee director compensation policy, aligning his incentives with shareholder interests through equity-based pay instead of only cash fees.
When do Alvin Shih’s Zevra (ZVRA) stock options expire?
The stock options expire on June 3, 2036, providing a long-term window to exercise once vested. After that expiration date, any unexercised options become worthless and can no longer be used to purchase Zevra common shares at the fixed exercise price.